Sie finden wissenschaftliche Informationen zu den
meisten Studien in englisch unter Database on Clinical
Studies and Case Reports
·
Verbesserung
der Symptome bzw. positiver Tenor der Autoren
o
Keine
relevante Veränderung der Symptome bzw. negativer Tenor der Autoren
v Verschlechterung der
Symptome
·
Artim
R, DiBella N. Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ) for
refractory nausea and vomiting (N/V). Proceedings of the
American Society for Clinical Oncology 1983;2:84.
·
Chang AE, Shiling DJ, Stillman RC, Goldberg NH,
Seipp CA, Barofsky I. Delta-9-tetrahydrocannabinol as an antiemetics in cancer
patients receiving high-dose methotrexate. Annals of Internal Medicine
1979;91:819-824.
o
Chang AE, Shiling DJ, Stillman RC, Goldberg NH,
Seipp CA, Barofsky I, Rosenberg SA.. A prospective evaluation of
delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin
and cytoxan chemotherapy. Cancer
1981; 47: 1746-1751.
·
Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen
EG. The antiemetic activity of tetrahydrocanabinol versus metoclopramide and
thiethylperazine in patients undergoing cancer chemotherapy. New Zealand
Medical Journal 1980;91:449-451.
·
Ekert H, Waters KD, Jurk KH, Mobilia J,
Loughnan P. Ameriloration of cancer chemotherapy-induced nausea and vomiting by
delta-9-tetrahydrocannabinol. Medical Journal of Australia 1979;2:657-659.
·
Frytak S, Moertel CG, O'Fallon JR, Rubin J,
Creagan ET, O'Connnell MJ. Delta-9-tetrahydrocannabinol as an antiemetics for
patients receiving cancer chemotherapy. A comparison with prochlorperazine and
a placebo. Annals of Internal Medicine 1979;91:825-830.
·
Gralla RJ, Tyson LB, Bordin LA, Clark RA,
Kelsen DP, Kris MG. Antiemetic therapy: a review of recent studies and a report
of a random assignment trial comparing metoclopramide with
delta-9-tetrahydrocannabinol. Cancer Treatment Report 1984;68:163-172.
·
Kluin-Nelemans JC, Nelemans FA, Meuwissen
OJATh, Maes RAA. D9-tetrahydrocannabinol (THC) as an antiemetic in
patients treated with cancer chemotherapy; a double-blind cross-over trial
against placebo. Veterinary and Human Toxicology 1979;21:338-340.
·
Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers
JL, Hamm J. Dronabinol and prochlorperazine in combination for treatment of
cancer chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom
Management 1991;6:352-359.
·
Levitt M, Faiman C, Hawks R, Wilson A.
Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and
marijuana as chemotherapy antiemetics. Proceedings of the American Society for
Clinical Oncology 1984;3:91.
·
Levitt M, Wilson A, Bowman D, Faiman C, Kemel
S, Krepart G. Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine
as chemotherapy antiemetics. Proceedings of the American Society for Clinical
Oncology 1981;22:422.
·
McCabe M, Smith FP, Goldberg D, Macdonald J,
Woolley PV, Warren R. Efficacy of tetrahydrocannabinol in patients refractory
to standard anti-emetic therapy. Investigational New Drugs 1988;6:243-246.
·
Neidhart JA, Gagen MM, Wilson HE, Young DC.
Comparative trial of the antiemetic effects of THC and haloperidol. International Journal of Clinical
Pharmacology Research 1981; 21: 38-42S.
·
Orr LE, McKernan JF, Bloome B. Antiemetic
effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in
chemotherapy-associated nausea and emesis. Archives of Internal Medicine
1980;140:1431-433.
·
Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer. A randomized
comparison of delta-9-tetrahydrocannabinol and prochlorperazine. New England
Journal of Medicine 1980;302:135-138.
·
Sallan SE, Zinberg NE, Frei E. Antiemetic
effect of delta-9-tetrahydrocannabinol in patients receiving cancer
chemotherapy. New England Journal of Medicine 1975;293:795-797.
·
Ungerleider JT, Andrysiak T, Fairbanks L,
Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy. A comparison
of oral delta-9-THC and prochlorperazine. Cancer 1982;50:636-645.
·
Ungerleider JT, Sarna G, Fairbanks LA,
Goodnight J, Andrysiak T, Jamison K. THC or compazine for the cancer
chemotherapy patient - the UCLA study. Part II: patient drug preference.
American Journal of Clinical Oncology 1985; 8: 142-147.
·
Meiri E, Jhangiani H, Vredenburgh JJ, Barbato
LM, Carter FJ, Yang HM, Baranowski V. Efficacy of dronabinol alone and in
combination with ondansetron versus ondansetron alone for delayed
chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007;23(3):533-43.
·
Levitt M, Faiman C, Hawks R, Wilson A.
Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and
marijuana as chemotherapy antiemetics. Proceedings of the American Society for
Clinical Oncology 1984;3:91.
·
Ahmedzai S, Carlyle DL, Clader IT, Moran F.
Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung
cancer chemotherapy. British Journal of Cancer 1983;48:657-663.
·
Chan HS, Correia JA, MacLeod SM. Nabilone
versus prochlorperazine for control of cancer chemotherapy-induced emesis in
children: a double-blind, crossover trial. Pediatrics 1987; 79: 946-952
·
Crawford SM, Buckman R. Nabilone and
metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a
double blind study. Medical Oncology
and Tumor Pharmacotherapy 1986; 3: 39-42.
·
Cunningham D,
Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, et al. A randomized
trial of oral nabilone and prochlorperazine compared to intravenous
metoclopramide and dexamethasone in the treatment of nausea and vomiting
induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
European Journal of Cancer and Clinical Oncology 1988; 24: 685-689.
·
Dalzell
AM, Bartlett H, Lilleyman JS. Nabilone: An alternative
antiemetic for cancer chemotherapy. Archives of Disease in Childhood
1986;61:502-505.
·
Einhorn LH, Nagy C, Furnas B, Williams SD.
Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.
Journal of Clinical Pharmacology. 1981 Aug-Sep;21(8-9 Suppl):64S-69S.
·
George M, Pejovic MH, Thuaire M, Kramar A,
Wolff JP. Randomized comparative trial of a new anti-emetic: nabilone, in
cancer patients treated with cisplatin. Biomedicine
and Pharmacotherapy 1983; 37: 24-27.
·
Herman
TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in
patients receiving cancer chemotherapy. New
England Journal of Medicine 1979; 300: 1295-1297.
·
Johansson R, Kilkku P, Groenroos M. A
double-blind, controlled trial of nabilone vs prochlorperazine for refractory
emesis induced by cancer chemotherapy. Cancer
Treatment Reviews 1982; 9: 25-33.
·
Jones SE, Durant JR, Greco FA, Robertone A. A
multi-institutional phase III study of nabilone vs placebo in
chemotherapy-induced nausea and vomiting. Cancer Treatment Reviews 1982; 9: 45-48
·
Levitt M. Nabilone vs placebo in the treatment
of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treatment Reviews 1982;
9(suppl B): 49-53.
·
Nagy CM, Furnas BE, Einhorn LH, Bond WH.
Nabilone: antiemetic crossover study in cancer chemotherapy patients.
Proceedings of the American Society for Cancer Research 1978;19:30.
·
Niederle
N, Schutte J, Schmidt CG. Crossover comparison of the
antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous
testicular cancer receiving cisplatin therapy. Klinische Wochenschrift 1986; 64: 362-365.
·
Niiranen Aila, Mattson K. A cross-over
comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy.
American Journal of Clinical Oncology 1985;8:336-340.
·
Pomeroy M, Fennelly JJ, Towers M. Prospective
randomized double-blind trial of nabilone versus domperidone in the treatment
of cytotoxic-induced emesis. Cancer Chemotherapy and Pharmacology
1986;17:285-288.
·
Priestman SG, Priestman TJ, Canney PA. A
double-blind randomised cross-over comparison of nabilone and metoclopramide in
the control of radiation-induced nausea. Clinical
Radiology 1987; 38: 543-544.
·
Steele N, Gralla RJ, Braun Jr DW, Young CW.
Double-blind comparison of the antiemetic effects of nabilone and
prochlorperazine on chemotherapy-induced emesis. Cancer Treatment Report 1980; 64: 219-224.
·
Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota
CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs. placebo
in cancer chemotherapy. Cancer
Treatment Reviews 1982; 9(Suppl B): 39-44
·
Citron ML, Herman TS, Vreeland F, Krasnow SH,
Fossieck BE, Jr. Antiemetic efficacy of levonantradol compared to
delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Cancer Treatment Reports 1985;69:109-112.
·
Higi
M, Niederle N, Bremer K, Schmitt G, Schmidt CG, Seeber S. Levonantradol bei der
Behandlung von zytostatika-bedingter Übelkeit und Erbrechen. Deutsche Medizinische Wochenschrift
1982; 107: 1232-1234.
·
Hutcheon
AW, Palmer JB, Soukop M, Cunningham D, McArdle C, Welsh J, et al. A randomised multicentre single blind comparison of a cannabinoid
anti-emetic (levonantradol) with ychlorpromazine in patients receiving their
first cytotoxic chemotherapy. European
Journal for Cancer and Clinical Oncology 1983; 19: 1087-1090
·
Stambaugh Jr JE, McAdams J, Vreeland F. Dose
ranging evaluation of the antiemetic efficacy and toxicity of intramuscular
levonantradol in cancer subjects with chemotherapy-induced emesis. International Journal of Clinical
Pharmacology Research1984; 24: 480-485
·
Abrahamov A, Abrahamov A, Mechoulam R. An
efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences
1995;56:2097-2102.
·
Vinciguerra V, Moore T, Brennan E. Inhalation
marijuana as an antiemetic for cancer chemotherapy. New York State Journal of
Medicine 1988;88:525-527.
·
Musty RE, Rossi R. Effects of smoked cannabis
and oral delta-9-tetrahydrocannabinol on nausea and emesis after cancer
chemotherapy: A review of state clinical trials. J Cannabis Ther
2001;1(1):29-42.
·
Doblin
RE, Kleiman MA. Marijuana as antiemetic medicine: a survey of
oncologists' experiences and attitudes. American
Journal of Clinical Oncology 1991; 9: 1314-1319.
o
Schwartz RH, Voth EA, Sheridan MJ. Marijuana to
prevent nausea and vomiting in cancer patients: a survey of clinical
oncologists. South Medical Journal 1997;90(2):167-72.
·
Ungerleider
JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG. Tetrahydrocannabinol
vs. prochlorperazine. The effects of two
antiemetics on patients undergoing radiotherapy. Radiology
1984;150(2):598-9.
·
Lucraft HH, Palmer MK. Randomised
clinical trial of levonantradol and chlorpromazine in the prevention of
radiotherapy-induced vomiting. Clinical Radiology 1982; 33: 621-622.
·
Zutt
M, Hanssle H, Emmert S, Neumann C, Kretschmer L. [Dronabinol for supportive
therapy in patients with malignant melanoma and liver metastases] [Article in
German]. Hautarzt 2006;57(5):423-7.
·
Gonzalez-Rosales F, Walsh D. Intractable nausea
and vomiting due to gastrointestinal mucosal metastases relieved by
tetrahydrocannabinol (dronabinol). Journal of Pain and Symptom Management
1997;14(5):311-314.
·
Layeeque
R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A, Klimberg VS. Prevention of nausea and vomiting following breast surgery. Am J Surg
2006;191(6):767-72.
·
Lewis IH, Campbell DN, Barrowcliffe MP. Effect
of nabilone on nausea and vomiting after total abdominal hysterectomy. British Journal of Anaesthesia 1994;
73: 244-246.
·
de
Jong BC, Prentiss D, McFarland W, Machekano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral
therapy among HIV-infected persons with
moderate to severe nausea. J Acquir Immune Defic Syndr
2005;38(1):43-6.
·
Woolridge E, Barton S, Samuel J, Osorio J,
Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical
symptoms. J Pain Symptom Manage 2005;29(4):358-67.
·
Sidney S. Marijuana use in HIV-positive and
AIDS patients: Results of a an anonymous mail survey. J Cannabis Ther
2001;1(3-4):35-43.
·
Costiniuk CT, Mills E, Cooper CL. Evaluation of
oral cannabinoid-containing medications for the management of interferon and
ribavirin-induced anorexia, nausea and weight loss in patients treated for
chronic hepatitis C virus. Can J Gastroenterol 2008;22(4):376-80.
·
Sylvestre DL, Clements BJ, Malibu Y. Cannabis
use improves retention and virological outcomes in patients treated for
hepatitis C. Eur J Gastroenterol Hepatol 2006;18(10):1057-63.
·
Curry W-NL. Hyperemesis gravidarum and clinical
cannabis: To eat or not to eat? J Cannabis Ther 2002;2(3-4):63-83.
·
Westfall RE, Janssen PA, Lucas P, Capler R.
Survey of medicinal cannabis use among childbearing women: patterns of its use
in pregnancy and retroactive self-assessment of its efficacy against 'morning
sickness'. Complement Ther Clin Pract 2006;12(1):27-33.
·
Merriman
AR, Oliak DA. Use of medical marijuana for treatment of severe
intractable nausea after laparoscopic Roux-en-Y gastric bypass surgery: case
report. Surg Obes Relat Dis, 26 January 2008 [Electronic publication ahead of
print])
·
Soderpalm AH, Schuster A, de Wit H. Antiemetic
efficacy of smoked marijuana: subjective and behavioral effects on nausea
induced by syrup of ipecac. Pharmacology, Biochemistry and Behavior 2001;69(3-4):343-50.
·
Beal
JE, Olson R, Laubenstein L, Morales JP, Bellman P, Yangco B, Lefkowitz L,
Plasse TF, Shepard KV. Dronabinol as a treatment
for anorexia associated with weight loss in patients with AIDS. Journal of Pain
and Symptom Management 1995;10(2):89-97.
·
Timpone JG, Wright DJ, Li N, Egorin MJ, Enama
ME, Mayers J, Galetto G, and the DATRI 004 Study Group. The safety and
pharmacokinetics of single-agent and combination therapy with megestrol acetate
and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and
Human Retroviruses 1997;13:305-315.
·
Abrams DI, Hilton JF, Leiser RJ, Shade SB,
Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG,
Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term
effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003;139(4):258-66.
·
Haney M, Rabkin J, Gunderson E, Foltin RW.
Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric
intake and mood. Psychopharmacology (Berl) 2005;181(1):170-8.
·
Haney M, Gunderson EW, Rabkin J, Hart CL,
Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive
marijuana smokers. Caloric intake, mood, and sleep. J
Acquir Immune Defic Syndr 2007;45(5):545-54.
·
Haney
M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and
marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and
mood. Psychopharmacology (Berl) 2005;181(1):170-8.
·
Haney M, Gunderson EW, Rabkin J, Hart CL,
Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive
marijuana smokers. Caloric intake, mood, and sleep. J
Acquir Immune Defic Syndr 2007;45(5):545-54.
·
Gorter R, Seefried M, Volberding P. Dronabinol
effects on weight in patients with HIV infection. AIDS 1992;6:127.
·
Plasse TF, Gorter RW, Krasnow SH, Lane M,
Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol.
Pharmacology, Biochemistry and Behavior 1991;40:695-700.
·
Plasse T, Conant M, Gorter R, Shepard KV.
Dronabinol stimulates appetite and causes weight gain in HIV patients.
International Conference on AIDS 1992;8(3):122 (abstract no. PuB 7442).
·
Struwe M, Kaempfer SH, Geiger CJ, Pavia AT,
Plasse TF, Shepard KV, Ries K, Evans TG. Effect of dronabinol on nutritional
status in HIV infection. Annals of Pharmacotherapy 1993;27:827-831.
·
Beal JE, Olson R, Lefkowitz L, Laubenstein L,
Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW,
Shepard KV. Long-term efficacy and safety of dronabinol for acquired
immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom
Management 1997;14(1):7-14.
·
Dejesus E, Rodwick BM, Bowers D, Cohen CJ,
Pearce D. Use of dronabinol improves appetite and reverses weight loss in
HIV/AIDS-infected patients. J Int Assoc Physicians AIDS Care 2007;6(2):95-100.
·
Prentiss
D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns
of marijuana use among patients with HIV/AIDS followed in a public health care
setting. J Acquir Immune Defic Syndr 2004;35(1):38-45.
·
Woolridge E, Barton S, Samuel J, Osorio J,
Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical
symptoms. J Pain Symptom Manage 2005;29(4):358-67.
·
Sidney S. Marijuana use in HIV-positive and
AIDS patients: Results of a an anonymous mail survey. J Cannabis Ther
2001;1(3-4):35-43.
·
Jatoi
A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S,
Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus
megestrol acetate versus combination therapy for cancer-associated anorexia: a
North Central Cancer Treatment Group study. Journal
of Clinical Oncology 2002;20(2):567-573.
·
Regelson
W, Butler JR, Schulz J, Kirk T, Peek L, Green ML, Zalis MO. Delta-9-tetrahydrocannabinol as an effective antidepressant and
appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara
S, editors. Pharmacology of marihuana. Vol 2. New York: Raven Press, 1976.
p. 763-776.
·
Wadleigh R, Spaulding GM, Lumbersky B, Zimmer
M, Shepard K, Plasse T. Dronabinol enhancement of appetite in cancer patients.
Proc Am Soc Oncology 1990; 9: 331.
o Strasser F,